Covovax: Decision on ‘Covovax’ tomorrow amidst the threat of Corona! Will be used as a booster dose – Govt Panel Likely To Decide On Covovax As A Heterologous Booster Dose For Adults On Wednesday Updates

0
13


Corona.  symbolic picture

Corona. symbolic picture
– Photo: Social Media

hear the news

Amid the threat of corona, the government panel may take a decision on Covax as a booster dose of corona for adults on Wednesday. An expert panel of the Central Drug Regulatory Authority may decide on Wednesday to approve the Serum Institute of India’s (SII) corona vaccine ‘Kovovax’ to be launched in the market. Official sources said that the dose of Covax can be given to those who have received both doses of Covishield or Covaxin.

The meeting of the subject expert committee of the Central Drugs Standard Control Organization (CDSCO) is scheduled to be held on January 11. Prakash Kumar Singh, director of government and regulatory affairs at the Serum Institute of India (SII), recently wrote a letter to the Drugs Controller General of India (DCGI), asking for approval of Covax as a booster dose for adults went. An official source said that amid the rising situation of the epidemic in some countries, an appeal was made to take an early decision on this.

DCGI approved on 28 December 2021 for use in emergency situations for adults with conditions. Covax was then approved for children aged 12-17 on 9 March 2022 and for children aged 7-11 on 28 June 2022 with certain conditions.

Covovax is manufactured by SII through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. It was included in the emergency-use list by the World Health Organization (WHO) on 17 December 2021. In August 2020 US-based vaccine maker Novavax Inc announced a license agreement with SII for the development and commercialization of its corona vaccine candidate NVX-CoV2373 in India and low-middle-income countries.

Expansion

Amid the threat of corona, the government panel may take a decision on Covax as a booster dose of corona for adults on Wednesday. An expert panel of the Central Drug Regulatory Authority may decide on Wednesday to approve the Serum Institute of India’s (SII) corona vaccine ‘Kovovax’ to be launched in the market. Official sources said that the dose of Covax can be given to those who have received both doses of Covishield or Covaxin.

The meeting of the subject expert committee of the Central Drugs Standard Control Organization (CDSCO) is scheduled to be held on January 11. Prakash Kumar Singh, director of government and regulatory affairs at the Serum Institute of India (SII), recently wrote a letter to the Drugs Controller General of India (DCGI), asking for approval of Covax as a booster dose for adults went. An official source said that amid the rising situation of the epidemic in some countries, an appeal was made to take an early decision on this.

DCGI approved on 28 December 2021 for use in emergency situations for adults with conditions. Covax was then approved for children aged 12-17 on 9 March 2022 and for children aged 7-11 on 28 June 2022 with certain conditions.

Covovax is manufactured by SII through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. It was included in the emergency-use list by the World Health Organization (WHO) on 17 December 2021. In August 2020 US-based vaccine maker Novavax Inc announced a license agreement with SII for the development and commercialization of its corona vaccine candidate NVX-CoV2373 in India and low-middle-income countries.